Intradigm Corporation

Palo Alto, United States Founded: 2000 • Age: 26 yrs Acquired By Silence Therapeutics
Develops RNA interference (RNAi) therapeutics for the treatment of cancer.

About Intradigm Corporation

Intradigm Corporation is a Healthcare company based in Palo Alto (United States) founded in 2000, and was acquired by Silence Therapeutics in December 2009. It develops RNA interference (RNAi) therapeutics for the treatment of cancer. It operates in the Healthcare and Technology sectors. Intradigm Corporation has raised $37.4 million across 2 funding rounds from investors including Roche, Novartis and Silence Therapeutics. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Denali Therapeutics, C4 Therapeutics and Erasca; 3 of its 3 listed competitors have raised funding.

Company details

Intradigm Corporation was founded in 2000 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where RNA interference therapeutics are developed for serious diseases, starting with oncology. Operations involve the use of proprietary Nanoplex delivery technology, which allows targeted administration to specific tissues via systemic drug delivery methods.

Key Metrics
  • Total Equity Funding
    $37.4M (USD)

    in 2 rounds

  • Latest Funding Round
    $21.4M (USD), Series B

    Jan 2009

  • Investors
    Roche

    & 10 more

  • Acquired by

Funding Insights of Intradigm Corporation

Intradigm Corporation has successfully raised a total of $37.4M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $21.4 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $37.4M
  • Total Rounds 2
  • Last Round Series B β€” $21.4M
  • First Round $16M

    (May 2006)

  • Investors Count 10

All 2 funding rounds of Intradigm Corporation with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2009$21.4MSeries B–Astellas Venture Management
May 2006$16MSeries A––
Valuation history

11 investors in total: 11 institutional.

Investors in Intradigm Corporation

Intradigm Corporation has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Novartis and Silence Therapeutics.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
A venture capital firm focused on life science innovations.
mp-healthcare.comCambridge, United States
Healthcare sector private equity investments are managed by the firm.
1991frazierhealthcare.comSeattle, United States
astellasventure.com
Venture capital firm focused on healthcare companies
altapartners.comJackson, United States
Early-stage life sciences investments are targeted in the healthcare sector.
lillyventures.comIndianapolis, United States
Genetic testing and analysis services are provided by MediBIC Group.
2000medibic.comChiba, Japan
R&D focused on manufacturing of drugs for multiple therapeutic areas
1996novartis.comBasel, Switzerland
Pharmaceuticals and diagnostics kits are developed for various diseases.
1896roche.comBasel, Switzerland
etpventures.com
R&D company focused on manufacturing drugs for multiple therapeutic areas
1976gene.comSan Francisco, United States
Premium access

Investor details for Intradigm Corporation

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Intradigm Corporation

4 dated milestones of Intradigm Corporation across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Intradigm Corporation is founded.
  2. Funding First funding round of $16.0M.
  3. Funding Latest funding round, Series B, of $21.4M.
  4. Exit Acquired by Silence Therapeutics.

Competitors of Intradigm Corporation

Intradigm Corporation has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, C4 Therapeutics and Erasca.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
denalitherapeutics.com2015San Francisco, United States$347M377
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
c4therapeutics.com2016Cambridge, United States$223M121
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
erasca.com2018San Diego, United States$300M120
Small molecule therapeutics for cancer treatment are developed.
Premium access

Detailed competitors of Intradigm Corporation

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Intradigm Corporation (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Intradigm Corporation

Premium access

Complete news archive for Intradigm Corporation

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Intradigm Corporation

Intradigm Corporation was founded in 2000 and raised its 1st funding round 6 years after it was founded.

Intradigm Corporation is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.

Intradigm Corporation is a funded company, having raised a total of $37.4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on May 2006.

Intradigm Corporation was founded in 2000 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where RNA interference therapeutics are developed for serious diseases, starting with oncology. Operations involve the use of proprietary Nanoplex delivery technology, which allows targeted administration to specific tissues via systemic drug delivery methods.

Intradigm Corporation's top competitors include C4 Therapeutics, Erasca and Denali Therapeutics.

Intradigm Corporation has 11 investors. Key investors include Roche, Novartis, Silence Therapeutics, Genentech, and Frazier Healthcare Partners.

Intradigm Corporation operates through Intradigm Corporation.

Yes. Intradigm Corporation was acquired by Silence Therapeutics in December 2009.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available